3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
5
Breast Neoplasms
5
Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
mCRPC
1
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Hepatoblastoma
1
Hemangiosarcoma
1
Extensive Stage Lung Small Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Adenocarcinoma
1
Interventions
talazoparib
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
mCRPC
×
talazoparib
×
90 days
×
Clear all
NCT03395197
2026-04-22
TALAPRO-2
Pfizer
Phase 3
Active not recruiting
1,054 enrolled
21 charts
1 FDA